Kenvue vs Sanofi

Skin360 BIPA Class Action $4.7M Settlement Notice Issued

A proposed class action settlement has been reached in Helene Melzer, et al. v. Johnson & Johnson Consumer Inc. (now Kenvue Brands LLC), pending in the U.S. District Court for the District of New Jersey. The lawsuit alleged that the defendant violated the Illinois Biometric Information Privacy Act (BIPA) by collecting, storing, and profiting from biometric data of individuals who used the Skin360 skin assessment app in Illinois between December 9, 2019, and May 5, 2023. The settlement establishes a $4.7 million fund to compensate class members who submit valid claims. Eligible individuals must file a claim by November 25, 2026. The defendant denies wrongdoing, and the settlement is subject to final court approval at a hearing scheduled for December 17, 2026.

• Settlement fund of $4.7 million established for class members.
• Class covers Illinois residents who used Skin360 app via mobile or web between Dec 9, 2019 and May 5, 2023.
• Claim deadline is November 25, 2026.

Affiliate Content Drives 42% of US TikTok Shop GMV

A new analysis by marketing agency Front Row highlights the growing importance of affiliate creators for TikTok Shop sales. In 2025, US TikTok Shop sales reached $15.8 billion, up 108% year-over-year, with projections of $23.4 billion by end of 2026. Affiliate creator content now drives 42% of total TikTok Shop GMV in the US, making it the largest sales channel on the platform. Mid-tier creators (10k-100k followers) convert at 4.2%, nearly double that of influencers with over a million followers. The article outlines a three-tier affiliate program structure (open, target, VIP) and presents a case study with Jergens, where a coordinated affiliate and paid media campaign achieved 230% ROAS and a 20,177% increase in sales over baseline.

• US TikTok Shop sales hit $15.8 billion in 2025, up 108% year-over-year.
• Affiliate creator content drives 42% of total TikTok Shop GMV in the US.
• Mid-tier creators (10k-100k followers) convert at 4.2%, nearly double the rate of accounts with over a million followers.

Investor Presentation Released: Kenvue

AI parsed presentation narrative: Kenvue is focused on driving growth as an independent consumer health leader while executing a major structural transition through a pending merger with Kimberly-Clark. Management's thesis centers on the 'Our Vue Forward' initiative to optimize its operating model and supply chain, aiming for $200 million in annualized gross savings to fuel investment in its iconic brand portfolio. Key tailwinds mentioned: 2026 Restructuring Initiative, Kimberly-Clark Merger.

6-K Financial Filing Analysis for Sanofi (2026-09-17)

Am 17. September 2026 reichte Sanofi ein Form 6-K bei der U.S. Securities and Exchange Commission ein, das eine Pressemitteilung vom 14. September 2026 beinhaltet. Die Einreichung kündigt eine neue strategische Partnerschaft zwischen Sanofi und Cheplapharm im Bereich etablierter Medikamente (Mature Medicines) an. Diese Partnerschaft unterstreicht Sanofis kontinuierliche Strategie zur Portfolio-Optimierung, um etablierte pharmazeutische Produkte effizienter zu verwalten oder zu monetarisieren und Ressourcen auf innovative Pipeline-Therapien und Kernwachstumstreiber zu fokussieren.

• Sanofi hat eine strategische Partnerschaft mit Cheplapharm für sein Portfolio an etablierten Medikamenten (Mature Medicines) geschlossen, die am 14. September 2026 per Pressemitteilung bekannt gegeben wurde.
• Die Form 6-K-Meldung wurde am 17. September 2026 offiziell von Alexandra Roger, Head of Legal Corporate & Finance, unterzeichnet und eingereicht.

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Agentic AI Transforming Pharma Marketing for Rare Diseases

This article discusses how agentic AI is poised to revolutionize pharmaceutical marketing, particularly for rare disease treatments. With traditional drug development costing $2.6 billion and taking 12-15 years, AI is compressing discovery timelines and enabling treatments for smaller patient populations, with rare disease approvals now exceeding 50% of FDA approvals. However, this precision medicine creates a marketing challenge: reaching small, specific audiences efficiently. The article argues that while programmatic advertising optimized campaign execution, agentic AI can synthesize vast healthcare, audience, and market data to provide actionable commercial insights, forecast patient need, and continuously adapt strategies. Early tests show marketing planning cycles collapsing by up to 10x. This approach aims to make more treatments commercially viable, improving treatment economics and driving further investment.

• The pharma industry invests $2.6 billion on average to bring a new treatment to market, taking 12 to 15 years with a 10% success rate.
• Rare disease approvals now account for over 50% of FDA drug approvals, up from below 30% a decade ago.
• Sanofi is developing a 'lab-in-a-loop' using AI agents to compress discovery work from years to weeks.